摘要
目的:观察吉西他滨联合顺铂对非小细胞肺癌(NSCLC)术后化疗的疗效及安全性。方法:116例经手术治疗的NSCLC患者随机分为观察组和对照组,分别在术后给予GP化疗方案(吉西他滨+顺铂)和NP化疗方案(长春瑞滨+顺铂),21 d为1周期,化疗4个周期。比较两组近期疗效、药品不良反应和1年复发率。结果:观察组总缓解率为48.28%(28/58),对照组总缓解率为46.55%(27/58),两组比较,差异无统计学意义(P>0.05)。两组Ⅲ+Ⅳ级的胃肠道反应、贫血、白细胞减少、粒细胞减少和血小板减少发生率比较,差异均无统计学意义(P>0.05)。观察组和对照组1年复发率分别为10.34%(6/58)和13.79%(8/58),差异无统计学意义(P>0.05)。结论:吉西他滨联合顺铂辅助NSCLC术后化疗的疗效、药品不良反应及1年复发率均与NP方案相当。
Objectlve：To in;eestigate the efficacy and safety of postoperative adjuvant chemotherapy with gemcita- bine combined with Cisplatin in the treatment of non-small cell lung cancer（NSCLC）. Methods： 116 cases patients with NSCLC ungerwent surgery were randomly divided into observation group and control group. GP（＇gemcitabine ＋ cisplatin） or NP（vinorelbine ＋ cisplatin） chemotherapy regimen were treated respectively for 4 cycles with each for 21 days. The recent curative effect, adverse reactions and one-year recurrence rate were compared between the two groups. Results：The overall response rate was 48.28% （28/58） in observation group, campared to 46.55% （27/58） in control group, there had no statistical significance （P 〉 0.05）. Compared the incidences of ]1[ ＋ 1V levels of gastrointestinal reaction, anemia, leuko- penia, granulocytopenia and thrombocytopenia between the two groups, there had no statistical significance （ P 〉 0.05 ）. The one-year recurrence rate was 10.34% （6/58） in observation group and 13.79% （8/58） in control ＇group, which had no statistical significance （ P 〉 0.05 ）. Conclusion： Gemcitabine combined with cisplatin on postoperative adjuvant chemo- therapy in NSCLC had distinct curative effect, tolerance of adverse reaction and low 10ng-term recurrence rate, which were all similar to NP chemotherapy regimen.
出处
《药物流行病学杂志》
CAS
2016年第1期3-5,共3页
Chinese Journal of Pharmacoepidemiology
基金
浙江省医药卫生一般研究计划(B类)(编号:2013KYB300)
关键词
辅助化疗
非小细胞肺癌
吉西他滨
顺铂
复发率
Adjuvant chemotherapy
Non-small cell lung cancer
Gemcitabine
Cisplatin
Recurrence rate
